15 Best Biotech Stocks to Buy According to Billionaires

4. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Billionaires: 14 

Dollar Value of Billionaire Holdings: $1,652,723,748 

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.  Its pharmacological portfolio, which includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others, focuses on medical areas with unmet needs.

Gilead Sciences, Inc. (NASDAQ:GILD)’s fiscal Q4 2024 revenue hit $7.6 billion, a 6% year-over-year increase. Its adjusted EPS increased by around 10.5% year over year to $1.90, exceeding analyst projections, while its GAAP EPS showed an increase of about 25% year over year.

Positive data is also shown by the company’s HIV revenues, which increased 8% to $19.6 billion in 2024, surpassing its 5% growth forecast. Biktarvy, an HIV medication, saw a 13% increase in full-year sales. The HIV division of Gilead Sciences, Inc. (NASDAQ:GILD) has had a history of steady growth, growing by 5% in 2022, 6% in 2023, and 8% in 2024. Its excellent execution and robust innovation are responsible for this growth.

Gilead Sciences, Inc. (NASDAQ:GILD) issued optimistic 2025 guidance in addition to these impressive results, anticipating much higher numbers and better performance. Non-GAAP diluted EPS is expected to be between $7.70 to $8.10 by management, as opposed to $4.62 for the entire year 2024.